View Item 

Show simple item record

A p38 Mitogen‐Activated Protein Kinase Inhibitor Arrests Active Alveolar Bone Loss in a Rat Periodontitis Model
dc.contributor.authorRogers, Jill E.
dc.contributor.authorLi, Fei
dc.contributor.authorCoatney, Derek D.
dc.contributor.authorOtremba, Jodie
dc.contributor.authorKriegl, Jaclynn M.
dc.contributor.authorProtter, Andrew A.
dc.contributor.authorHiggins, Linda S.
dc.contributor.authorMedicherla, Satyanarayana
dc.contributor.authorKirkwood, Keith L.
dc.date.accessioned2018-02-05T16:43:41Z
dc.date.available2018-02-05T16:43:41Z
dc.date.issued2007-10
dc.identifier.citationRogers, Jill E.; Li, Fei; Coatney, Derek D.; Otremba, Jodie; Kriegl, Jaclynn M.; Protter, Andrew A.; Higgins, Linda S.; Medicherla, Satyanarayana; Kirkwood, Keith L. (2007). "A p38 Mitogen‐Activated Protein Kinase Inhibitor Arrests Active Alveolar Bone Loss in a Rat Periodontitis Model." Journal of Periodontology 78(10): 1992-1998.
dc.identifier.issn0022-3492
dc.identifier.issn1943-3670
dc.identifier.urihttps://hdl.handle.net/2027.42/141943
dc.publisherAmerican Academy of Periodontology
dc.publisherWiley Periodicals, Inc.
dc.subject.otherp38 inhibitor
dc.subject.otherperiodontitis
dc.subject.othermitogen‐activated protein kinase
dc.subject.othercytokines
dc.subject.otherlipopolysaccharide
dc.subject.otherAlveolar bone loss
dc.titleA p38 Mitogen‐Activated Protein Kinase Inhibitor Arrests Active Alveolar Bone Loss in a Rat Periodontitis Model
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDentistry
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI.
dc.contributor.affiliationumOrthopedics Research Laboratory, University of Michigan.
dc.contributor.affiliationotherCurrently, Schering‐Plough, Kenilworth, NJ; previously, Scios.
dc.contributor.affiliationotherCurrently, InteKrin Therapeutics, Los Altos, CA; previously, Scios.
dc.contributor.affiliationotherCurrently, Medivation, San Franscisco, CA; previously, Scios, Fremont, CA.
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/141943/1/jper1992.pdf
dc.identifier.doi10.1902/jop.2007.070101
dc.identifier.sourceJournal of Periodontology
dc.identifier.citedreferenceWilson TG Jr. How patient compliance to suggested oral hygiene and maintenance affect periodontal therapy. Dent Clin North Am 1998; 42: 389 – 403.
dc.identifier.citedreferenceSuda T, Kobayashi K, Jimi E, Udagawa N, Takahashi N. The molecular basis of osteoclast differentiation and activation. Novartis Found Symp 2001; 232: 235 – 247.
dc.identifier.citedreferenceMahamed DA, Marleau A, Alnaeeli M, et al. G(‐) anaerobes‐reactive CD4+ T‐cells trigger RANKL‐mediated enhanced alveolar bone loss in diabetic NOD mice. Diabetes 2005; 54: 1477 – 1486.
dc.identifier.citedreferenceTeng YT, Nguyen H, Gao X, et al. Functional human T‐cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000; 106: R59 – R67.
dc.identifier.citedreferenceAdams JL, Badger AM, Kumar S, Lee JC. p38 MAP kinase: Molecular target for the inhibition of pro‐inflammatory cytokines. Prog Med Chem 2001; 38: 1 – 60.
dc.identifier.citedreferenceHoffmann E, Dittrich‐Breiholz O, Holtmann H, Kracht M. Multiple control of interleukin‐8 gene expression. J Leukoc Biol 2002; 72: 847 – 855.
dc.identifier.citedreferenceKirkwood K, Martin T, Andreadis ST, Kim YJ. Chemically modified tetracyclines selectively inhibit IL‐6 expression in osteoblasts by decreasing mRNA stability. Biochem Pharmacol 2003; 66: 1809 – 1819.
dc.identifier.citedreferencePatil C, Rossa CJ, Kirkwood K. Actinobacillus actinomycetemcomitans lipopolysaccharide induces interleukin‐6 expression through multiple mitogen‐activated protein kinase pathways in periodontal ligament fibroblasts. Oral Microbiol Immunol 2006; 21: 392 – 398.
dc.identifier.citedreferencePatil C, Zhu X, Rossa C Jr., Kim YJ, Kirkwood KL. p38 MAPK regulates IL‐1beta induced IL‐6 expression through mRNA stability in osteoblasts. Immunol Invest 2004; 33: 213 – 233.
dc.identifier.citedreferenceRossa C, Ehmann K, Liu M, Patil C, Kirkwood KL. MKK3/6‐p38 MAPK signaling is required for IL‐1beta and TNF‐alpha‐induced RANKL expression in bone marrow stromal cells. J Interferon Cytokine Res 2006; 26: 719 – 729.
dc.identifier.citedreferenceLee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000; 47: 185 – 201.
dc.identifier.citedreferenceMbalaviele G, Anderson G, Jones A, et al. Inhibition of p38 mitogen‐activated protein kinase prevents inflammatory bone destruction. J Pharmacol Exp Ther 2006; 317: 1044 – 1053.
dc.identifier.citedreferenceMedicherla S, Ma JY, Mangadu R, et al. A selective p38 alpha mitogen‐activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen‐induced arthritis. J Pharmacol Exp Ther 2006; 318: 132 – 141.
dc.identifier.citedreferenceKirkwood KL, Li F, Rogers JE, et al. A p38‐alpha selective mitogen activated protein kinase inhibitor prevents periodontal bone loss. J Pharmacol Exp Ther 2007; 320: 56 – 63.
dc.identifier.citedreferenceRogers JE, Li F, Coatney DD, et al. Actinobacillus actinomycetemcomitans lipopolysaccharide‐mediated experimental bone loss model for aggressive periodontitis. J Periodontol 2007; 78: 550 – 558.
dc.identifier.citedreferenceGuo L, Lim KB, Gunn JS, et al. Regulation of lipid A modifications by Salmonella typhimurium virulence genes phoP‐phoQ. Science 1997; 276: 250 – 253.
dc.identifier.citedreferenceKarimbux NY, Ramamurthy NS, Golub LM, Nishimura I. The expression of collagen I and XII mRNAs in Porphyromonas gingivalis ‐induced periodontitis in rats: The effect of doxycycline and chemically modified tetracycline. J Periodontol 1998; 69: 34 – 40.
dc.identifier.citedreferencePark C, Abramson Z, Taba M, et al. Three‐dimensional micro‐computed tomographic imaging of alveolar bone in experimental bone loss or repair. J Periodontol 2007; 78: 273 – 281.
dc.identifier.citedreferenceBaldock PA, Thomas GP, Hodge JM, et al. Vitamin D action and regulation of bone remodeling: Suppression of osteoclastogenesis by the mature osteoblast. J Bone Miner Res 2006; 21: 1618 – 1626.
dc.identifier.citedreferenceChristersson LA, Zambon JJ. Suppression of subgingival Actinobacillus actinomycetemcomitans in localized juvenile periodontitis by systemic tetracycline. J Clin Periodontol 1993; 20: 395 – 401.
dc.identifier.citedreferenceJeffcoat MK, Williams RC, Reddy MS, English R, Goldhaber P. Flurbiprofen treatment of human periodontitis: Effect on alveolar bone height and metabolism. J Periodontal Res 1988; 23: 381 – 385.
dc.identifier.citedreferenceWilliams RC, Jeffcoat MK, Howell TH, et al. Altering the progression of human alveolar bone loss with the non‐steroidal anti‐inflammatory drug flurbiprofen. J Periodontol 1989; 60: 485 – 490.
dc.identifier.citedreferenceCaton JG, Ciancio SG, Blieden TM, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol 2000; 71: 521 – 532.
dc.identifier.citedreferenceCiancio S, Ashley R. Safety and efficacy of sub‐antimicrobial‐dose doxycycline therapy in patients with adult periodontitis. Adv Dent Res 1998; 12: 27 – 31.
dc.identifier.citedreferenceReddy MS, Weatherford TW 3rd, Smith CA, West BD, Jeffcoat MK, Jacks TM. Alendronate treatment of naturally‐occurring periodontitis in beagle dogs. J Periodontol 1995; 66: 211 – 217.
dc.identifier.citedreferenceRocha M, Nava LE, Vazquez de la Torre C, Sanchez‐Marin F, Garay‐Sevilla ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: A randomized, placebo‐controlled trial. J Periodontol 2001; 72: 204 – 209.
dc.identifier.citedreferenceNiikura K. Vacuolar ATPase as a drug discovery target. Drug News Perspect 2006; 19: 139 – 144.
dc.identifier.citedreferenceAssuma R, Oates T, Cochran D, Amar S, Graves DT. IL‐1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol 1998; 160: 403 – 409.
dc.identifier.citedreferenceGraves DT, Delima AJ, Assuma R, Amar S, Oates T, Cochran D. Interleukin‐1 and tumor necrosis factor antagonists inhibit the progression of inflammatory cell infiltration toward alveolar bone in experimental periodontitis. J Periodontol 1998; 69: 1419 – 1425.
dc.identifier.citedreferenceWei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL‐1 mediates TNF‐induced osteoclastogenesis. J Clin Invest 2005; 115: 282 – 290.
dc.identifier.citedreferenceDelima AJ, Oates T, Assuma R, et al. Soluble antagonists to interleukin‐1 (IL‐1) and tumor necrosis factor (TNF) inhibits loss of tissue attachment in experimental periodontitis. J Clin Periodontol 2001; 28: 233 – 240.
dc.identifier.citedreferenceZwerina J, Hayer S, Tohidast‐Akrad M, et al. Single and combined inhibition of tumor necrosis factor, interleukin‐1, and RANKL pathways in tumor necrosis factor‐induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004; 50: 277 – 290.
dc.identifier.citedreferenceParasrampuria DA, de Boer P, Desai‐Krieger D, Chow AT, Jones CR. Single‐dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen‐activated protein kinase inhibitor: A first‐in‐human study. J Clin Pharmacol 2003; 43: 406 – 413.
dc.identifier.citedreferenceFu Q, Jilka R, Manolagas S, O’Brien C. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP‐response element‐binding protein. J Biol Chem 2002; 277: 48868 – 48875.
dc.identifier.citedreferenceKirkwood KL, Cirelli J, Rogers JE, Giannobile WV. Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 2007; 43: 294 – 315.
dc.identifier.citedreferenceLee HJ, Kang IK, Chung CP, Choi SM. The subgingival microflora and gingival crevicular fluid cytokines in refractory periodontitis. J Clin Periodontol 1995; 22: 885 – 890.
dc.identifier.citedreferenceLeng SX, Elias JA. Interleukin‐11 inhibits macrophage interleukin‐12 production. J Immunol 1997; 159: 2161 – 2168.
dc.identifier.citedreferenceChen CC, Chang KL, Huang JF, Huang JS, Tsai CC. Interleukin‐6 production by human gingival fibroblasts following stimulation with Actinobacillus actinomycetemcomitans (in Chinese). Kaohsiung J Med Sci 1998; 14: 367 – 378.
dc.identifier.citedreferenceTsai CC, Ho YP, Chen CC. Levels of interleukin‐1 beta and interleukin‐8 in gingival crevicular fluids in adult periodontitis. J Periodontol 1995; 66: 852 – 859.
dc.identifier.citedreferenceHaffajee AD, Socransky SS. Microbial etiological agents of destructive periodontal diseases. Periodontol 2000 1994; 5: 78 – 111.
dc.identifier.citedreferenceRoux S, Orcel P. Bone loss. Factors that regulate osteoclast differentiation: An update. Arthritis Res 2000; 2: 451 – 456.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jper1992.pdf
Size:
4.159MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.